ROIC
The Return on Invested Capital (aka ROIC) for Catella AB (publ) (OM:CAT B) is 0.228558. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Catella AB (publ) (OM:CAT B) is 1.885888. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Catella AB (publ) (OM:CAT B) is 0.163413.
Another useful indicator to assist in detmining rank is the ERP5 Rank. This is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Catella AB (publ) (OM:CAT B) is 1694. The lower the ERP5 rank, the more undervalued a company is thought to be.
The Current Ratio of Catella AB (publ) (OM:CAT B) is 1.35. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company has little trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.
Looking further, the MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Catella AB (publ) (OM:CAT B) is 1354. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.
Piotroski F-Score
The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Catella AB (publ) (OM:CAT B) is 6. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.
Gross Margin
The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Catella AB (publ) (OM:CAT B) is 11.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.
Price Index
The Price Index is a ratio that indicates the return of a share price over a past period. The price index of Catella AB (publ) (OM:CAT B) for last month was 1.12917. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month. If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for Catella AB (publ) (OM:CAT B) is 1.30093.
Shareholder Yield, Shareholder Yield (Mebane Faber)
The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt reduction. The Shareholder Yield of Catella AB (publ) (OM:CAT B) is 0.016595. This percentage is calculated by adding the dividend yield plus the percentage of shares repurchased. Dividends are a common way that companies distribute cash to their shareholders. Similarly, cash repurchases and a reduction of debt can increase the shareholder value, too. Another way to determine the effectiveness of a company’s distributions is by looking at the Shareholder yield (Mebane Faber). The Shareholder Yield (Mebane Faber) of Catella AB (publ) OM:CAT B is 1.39837. This number is calculated by looking at the sum of the dividend yield plus percentage of sales repurchased and net debt repaid yield.
The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Catella AB (publ) OM:CAT B is 1.445572. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for Catella AB (publ) (OM:CAT B) is 9.550458. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Catella AB (publ) (OM:CAT B) is 25.646737. This ratio is found by taking the current share price and dividing by earnings per share.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
The Current Ratio of PCI Biotech Holding ASA (OB:PCIB) is 21.01. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company does not have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations. It is wise to compare a company’s current ratio to that of other companies in the same industry. It would also be wise to look at the trend of the current ratio for a given company over a given time period.
Another useful indicator to assist in detmining rank is the ERP5 Rank. This is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of PCI Biotech Holding ASA (OB:PCIB) is 16441. The lower the ERP5 rank, the more undervalued a company is thought to be.
Looking further, the MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of PCI Biotech Holding ASA (OB:PCIB) is 15888. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.
Piotroski F-Score
The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of PCI Biotech Holding ASA (OB:PCIB) is 3. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.
The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of PCI Biotech Holding ASA (OB:PCIB) is 52.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.
The Price Index is a ratio that indicates the return of a share price over a past period. The price index of PCI Biotech Holding ASA (OB:PCIB) for last month was 0.99053. This is calculated by taking the current share price and dividing by the share price one month ago. If the ratio is greater than 1, then that means there has been an increase in price over the month.
If the ratio is less than 1, then we can determine that there has been a decrease in price. Similarly, investors look up the share price over 12 month periods. The Price Index 12m for PCI Biotech Holding ASA (OB:PCIB) is 0.45478.
Valuation
PCI Biotech Holding ASA (OB:PCIB) presently has a current ratio of 21.01. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.
The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of PCI Biotech Holding ASA (OB:PCIB) is 84. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of PCI Biotech Holding ASA (OB:PCIB) is 89.
The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for PCI Biotech Holding ASA OB:PCIB is 2.863487. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for PCI Biotech Holding ASA (OB:PCIB) is -32.130475. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for PCI Biotech Holding ASA (OB:PCIB) is -27.988988. This ratio is found by taking the current share price and dividing by earnings per share.
FCF
The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of PCI Biotech Holding ASA (OB:PCIB) is -0.049021.
Just-released report names Cannabis Stock of the Year for 2019! Their last pick has seen a +1,200% return since he released it! This stock has all of the makings of the next great cannabis stock – early-mover advantage, international exposure and influential partnerships, plus it has a product that is unlike anything else on the market… You will also receive a free, weekly newsletter to stay on top of the latest industry trends, read analysis on promising cannabis stocks, and more. Click here to receive your Free Report immediately! |